Screener
Charles River Laboratories CRL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | June 27, 2026 | December 27, 2025 |
|---|---|---|
| Liabilities, Redeemable Noncontrolling Interests and Equity | ||
| Current liabilities: | ||
| Accounts payable | $140,983 | $148,800 |
| Accrued compensation | 187,835 | 268,854 |
| Deferred revenue | 203,035 | 210,418 |
| Accrued liabilities | 380,101 | 270,085 |
| Other current liabilities | 222,792 | 222,158 |
| Total current liabilities | 1,134,746 | 1,120,315 |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's accrued expenses?
- Charles River Laboratories (CRL) reported accrued expenses of $187.84M in Q2 2026.
- How has Charles River Laboratories's accrued expenses changed year-over-year?
- Charles River Laboratories's accrued expenses decreased by 17.4% year-over-year, from $227.51M to $187.84M.
- What is the long-term trend for Charles River Laboratories's accrued expenses?
- Over 5 years (2020 to 2025), Charles River Laboratories's accrued expenses has grown at a 5.4% compound annual growth rate (CAGR), from $206.82M to $268.85M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Charles River Laboratories's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude